A Method to Improve Continuous Renal Replacement Therapy Circuit Survival Time in Critically Ill Coronavirus Disease 2019 Patients With Acute Kidney Injury

Meint Volbeda; Mark Londema; Matijs van Meurs; Coen A Stegeman; Ron T Gansevoort; Stefan P Berger; Peter H J van der Voort; Casper F M Franssen

doi:10.1097/CCE.0000000000000258

A Method to Improve Continuous Renal Replacement Therapy Circuit Survival Time in Critically Ill Coronavirus Disease 2019 Patients With Acute Kidney Injury

Meint Volbeda^*, Mark Londema, Matijs van Meurs, Coen A Stegeman, Ron T Gansevoort, Stefan P Berger, Peter H J van der Voort, Casper F M Franssen

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

100 Downloads (Pure)

Abstract

Objectives: Optimizing continuous renal replacement therapy circuit survival in coronavirus disease 2019 patients admitted to the ICU.

Design: Single-center prospective observational cohort study.

Setting: Tertiary academic teaching ICU.

Patients: Between March 19, 2020, and May 18, 2020, 11 out of 101 coronavirus disease 2019 patients were treated with continuous renal replacement therapy comprising 127 continuous renal replacement therapy days.

Interventions: A nonrandomized observational comparison of circuit anticoagulation modalities using standard regional citrate anticoagulation, continuous IV heparin anticoagulation, or the combination of regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin.

Measurements and Main Results: Circuit patency was shorter than 24 hours using standard regional citrate anticoagulation or continuous IV heparin anticoagulation. Median circuit survival increased with at least 165% when the combination of regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin was applied.

Conclusions: Continuous renal replacement therapy circuit patency is diminished in coronavirus disease 2019 ICU patients. Combining regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin increases filter survival as compared with regional citrate anticoagulation alone in this nonrandomized observational study.

Original language	English
Article number	e0258
Number of pages	3
Journal	Critical Care Explorations
Volume	2
Issue number	10
DOIs	https://doi.org/10.1097/CCE.0000000000000258
Publication status	Published - 2020

Access to Document

10.1097/CCE.0000000000000258Licence: CC BY-NC-ND

A Method to Improve Continuous Renal Replacement Therapy Circuit Survival Time in Critically Ill Coronavirus Disease 2019 Patients With Acute Kidney InjuryFinal publisher's version, 745 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

Volbeda, M., Londema, M., van Meurs, M., Stegeman, C. A., Gansevoort, R. T., Berger, S. P., van der Voort, P. H. J., & Franssen, C. F. M. (2020). A Method to Improve Continuous Renal Replacement Therapy Circuit Survival Time in Critically Ill Coronavirus Disease 2019 Patients With Acute Kidney Injury. Critical Care Explorations, 2(10), Article e0258. https://doi.org/10.1097/CCE.0000000000000258

@article{ab7ff3bf28374a71b85103a7c15d4ba7,

title = "A Method to Improve Continuous Renal Replacement Therapy Circuit Survival Time in Critically Ill Coronavirus Disease 2019 Patients With Acute Kidney Injury",

abstract = "Objectives: Optimizing continuous renal replacement therapy circuit survival in coronavirus disease 2019 patients admitted to the ICU.Design: Single-center prospective observational cohort study.Setting: Tertiary academic teaching ICU.Patients: Between March 19, 2020, and May 18, 2020, 11 out of 101 coronavirus disease 2019 patients were treated with continuous renal replacement therapy comprising 127 continuous renal replacement therapy days.Interventions: A nonrandomized observational comparison of circuit anticoagulation modalities using standard regional citrate anticoagulation, continuous IV heparin anticoagulation, or the combination of regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin.Measurements and Main Results: Circuit patency was shorter than 24 hours using standard regional citrate anticoagulation or continuous IV heparin anticoagulation. Median circuit survival increased with at least 165% when the combination of regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin was applied.Conclusions: Continuous renal replacement therapy circuit patency is diminished in coronavirus disease 2019 ICU patients. Combining regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin increases filter survival as compared with regional citrate anticoagulation alone in this nonrandomized observational study.",

author = "Meint Volbeda and Mark Londema and {van Meurs}, Matijs and Stegeman, {Coen A} and Gansevoort, {Ron T} and Berger, {Stefan P} and {van der Voort}, {Peter H J} and Franssen, {Casper F M}",

note = "Copyright {\textcopyright} 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.",

year = "2020",

doi = "10.1097/CCE.0000000000000258",

language = "English",

volume = "2",

journal = "Critical Care Explorations",

issn = "2639-8028",

publisher = "Wolters Kluwer",

number = "10",

}

Volbeda, M, Londema, M, van Meurs, M , Stegeman, CA , Gansevoort, RT , Berger, SP , van der Voort, PHJ & Franssen, CFM 2020, 'A Method to Improve Continuous Renal Replacement Therapy Circuit Survival Time in Critically Ill Coronavirus Disease 2019 Patients With Acute Kidney Injury', Critical Care Explorations, vol. 2, no. 10, e0258. https://doi.org/10.1097/CCE.0000000000000258

TY - JOUR

T1 - A Method to Improve Continuous Renal Replacement Therapy Circuit Survival Time in Critically Ill Coronavirus Disease 2019 Patients With Acute Kidney Injury

AU - Volbeda, Meint

AU - Londema, Mark

AU - van Meurs, Matijs

AU - Stegeman, Coen A

AU - Gansevoort, Ron T

AU - Berger, Stefan P

AU - van der Voort, Peter H J

AU - Franssen, Casper F M

PY - 2020

Y1 - 2020

N2 - Objectives: Optimizing continuous renal replacement therapy circuit survival in coronavirus disease 2019 patients admitted to the ICU.Design: Single-center prospective observational cohort study.Setting: Tertiary academic teaching ICU.Patients: Between March 19, 2020, and May 18, 2020, 11 out of 101 coronavirus disease 2019 patients were treated with continuous renal replacement therapy comprising 127 continuous renal replacement therapy days.Interventions: A nonrandomized observational comparison of circuit anticoagulation modalities using standard regional citrate anticoagulation, continuous IV heparin anticoagulation, or the combination of regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin.Measurements and Main Results: Circuit patency was shorter than 24 hours using standard regional citrate anticoagulation or continuous IV heparin anticoagulation. Median circuit survival increased with at least 165% when the combination of regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin was applied.Conclusions: Continuous renal replacement therapy circuit patency is diminished in coronavirus disease 2019 ICU patients. Combining regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin increases filter survival as compared with regional citrate anticoagulation alone in this nonrandomized observational study.

AB - Objectives: Optimizing continuous renal replacement therapy circuit survival in coronavirus disease 2019 patients admitted to the ICU.Design: Single-center prospective observational cohort study.Setting: Tertiary academic teaching ICU.Patients: Between March 19, 2020, and May 18, 2020, 11 out of 101 coronavirus disease 2019 patients were treated with continuous renal replacement therapy comprising 127 continuous renal replacement therapy days.Interventions: A nonrandomized observational comparison of circuit anticoagulation modalities using standard regional citrate anticoagulation, continuous IV heparin anticoagulation, or the combination of regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin.Measurements and Main Results: Circuit patency was shorter than 24 hours using standard regional citrate anticoagulation or continuous IV heparin anticoagulation. Median circuit survival increased with at least 165% when the combination of regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin was applied.Conclusions: Continuous renal replacement therapy circuit patency is diminished in coronavirus disease 2019 ICU patients. Combining regional citrate anticoagulation with either continuous IV heparin or therapeutic dose nadroparin increases filter survival as compared with regional citrate anticoagulation alone in this nonrandomized observational study.

U2 - 10.1097/CCE.0000000000000258

DO - 10.1097/CCE.0000000000000258

M3 - Article

C2 - 33134948

SN - 2639-8028

VL - 2

JO - Critical Care Explorations

JF - Critical Care Explorations

IS - 10

M1 - e0258

ER -

A Method to Improve Continuous Renal Replacement Therapy Circuit Survival Time in Critically Ill Coronavirus Disease 2019 Patients With Acute Kidney Injury

Abstract

Access to Document

Handle.net

Fingerprint

Cite this